Login / Signup

Delafloxacin, an alternative treatment for levofloxacin-resistant staphylococci in osteoarticular infections: To use or not to use?

Caroline LoïezAudrey CharletFanny LemonnierHenri MigaudÉric SennevilleClaire DuployezFrédéric Wallet
Published in: Diagnostic microbiology and infectious disease (2024)
Susceptibility of delafloxacin on 199 osteoarticular levofloxacin-resistant staphylococci strains was reported in 49% and 1% using SSTI S. aureus breakpoint (0.25 mg/L) and general S. aureus breakpoint (0.016 mg/L) respectively. Fifty percents levofloxacin-resistant staphylococci showed resistance to delafloxacin using CA-SFM/EUCAST recommendations. Microbiological societies should define new breakpoints especially for CoNS.
Keyphrases
  • antimicrobial resistance
  • escherichia coli
  • replacement therapy